Institutional shares held 43.7 Million
251K calls
79.2K puts
Total value of holdings $281M
$1.61M calls
$510K puts
Market Cap $302M
46,922,800 Shares Out.
Institutional ownership 93.05%
# of Institutions 185


Latest Institutional Activity in PRTA

Top Purchases

Q1 2025
Wellington Management Group LLP Shares Held: 5.2M ($33.5M)
Q1 2025
Nordea Investment Management Ab Shares Held: 308K ($1.98M)
Q1 2025
Siren, L.L.C. Shares Held: 1.28M ($8.27M)
Q1 2025
Nuveen, LLC Shares Held: 150K ($966K)
Q1 2025
Dcf Advisers, LLC Shares Held: 195K ($1.26M)

Top Sells

Q1 2025
State Street Corp Shares Held: 1.52M ($9.8M)
Q1 2025
Price T Rowe Associates Inc Shares Held: 3.46M ($22.3M)
Q1 2025
Federated Hermes, Inc. Shares Held: 546K ($3.52M)
Q1 2025
Rock Springs Capital Management LP Shares Held: 493K ($3.17M)
Q1 2025
Vanguard Group Inc Shares Held: 1.27M ($8.17M)

About PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.


Insider Transactions at PRTA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
637K Shares
From 2 Insiders
Bona fide gift 430K shares
Open market or private purchase 207K shares
Sell / Disposition
7.03M Shares
From 2 Insiders
Open market or private sale 6.28M shares
Bona fide gift 748K shares

Track Institutional and Insider Activities on PRTA

Follow PROTHENA CORP PUBLIC LTD CO and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRTA shares.

Notify only if

Insider Trading

Get notified when an Prothena Corp Public LTD CO insider buys or sells PRTA shares.

Notify only if

News

Receive news related to PROTHENA CORP PUBLIC LTD CO

Track Activities on PRTA